



# Quest for Growth

Press & Analyst Meeting

28 July 2017



## Agenda

- 2017 H1 results and performance Quest for Growth
- Comments on quoted portfolio
- Comments on unquoted portfolio
- Questions and Answers



## 2017 H1 results and performance Quest for Growth

### VALUATION QUEST FOR GROWTH

Stock Price	Net asset value/share		
	30/06/2017	31/05/2017	31/12/2016
8.04 EUR	10.36 EUR	10.46 EUR	8.91 EUR
Number of shares	15,155,969	15,155,969	15,155,969

Discount of the share price versus Net Asset Value: 22.42%

Source: Estimate by Capricorn Venture Partners NV


#### Key figures:

- Return on equity per share: 16.38% since 31 December 2016
- Net asset value per share at 30 June 2017: € 10,36 (31 December 2016: € 8.91)
- Net result for the period: +€ 22,104,883 (+ € 1.46 per share) against a loss of - € 3,191,501 (- € 0.26 per share) for H1 2016
- Share price at 30 June 2017: € 8.04 (31 December 2016: € 7.649)
- Discount of the share price versus net asset value: 22 % at 30 June 2017 (14 % at 31 December 2016)
- Positive impact of acquisition CHF portfolio company Ogeda on net asset value Quest for Growth: + € 8.6 million
- First time adoption of IFRS (Condensed Interim Financial Statements)
- EGM approves new structure




# 2017 H1 results and performance Quest for Growth

## Added value per sector per share






## 2017 H1 results and performance Quest for Growth Added value per asset class per share





# Quest for Growth NAV


Results from 1/01/2006 until 30/06/2017





# Quest for Growth share price


## 3 year total shareholders return





# Quest for Growth share price

Discount to Net Asset Value: 22 %









# Quest for Growth share price

## Portfolio composition and market capitalisation at 30/06/2017





## Distribution of the portfolio by sector at 30/06/2017





## Agenda

- 2017 H1 results and performance Quest for Growth
- Comments on quoted portfolio
- Comments on unquoted portfolio
- Questions and Answers



# Portfolio quoted

## Equity market environment

### Equity markets in 2017

Stock markets in Europe (STOXX 600), Small caps (Stoxx Small 200) & USA (S&P 500)							
Range	12/30/2016	-	06/30/2017	Period	Daily	No. of Period	182 Day(s)
Security	Currency	Price Change	Total Return	Difference	Annual Eq		
1) SXXP Index	EUR	4.97%	7.54%		15.69%		
2) SCXP Index	EUR	8.84%	11.01%	3.47%	23.30%		
3) SPX Index	EUR	.03%	1.04%	-6.49%	2.11%		




source: Bloomberg



# Portfolio quoted

## Equity market environment


### Equity markets in 2017






# Portfolio quoted Equity market environment Economic indicators

### ISM Manufacturing Index & US recessions (NBER)




### IFO index



source : ISM, NBER, IFO, Bloomberg, Capricorn Venture Partners



# Portfolio quoted Equity market environment Valuation





# Portfolio quoted Transactions 2017 H1

	IN	OUT	INCREASE	REDUCTION
JANUARY	DAX P put Jun-17	Kuka	EVS Kingspan Jensen-Group	Fresenius Melexis
FEBRUARY			Umicore	Melexis
MARCH				SAP Kiadis Pharma UDG Healthcare Jensen-Group
APRIL	DAX P put Dec-17	DAX P put Jun-17	EVS Gerresheimer	CFE Nexus
MAY	Axway Software Aures CEWE			Nexus Technotrans Bertrandt UDG Healthcare
JUNE	Kiadis warrant	Zetes	Axway CEWE Norma Group	Nexus Umicore Kiadis Pharma





# Portfolio quoted Transactions 2017 H1





## Portfolio quoted

Transactions: Introduction Aures



AURES Technologies engages in the design and marketing of point-of-sale (POS) computer terminals and specific systems intended primarily for businesses, supermarkets, hotels and restaurants. The company was founded in 1989 and is headquartered in Lisses, France.

### Key figures & ratios 30/06/17

Mkt. Cap. (m EUR)	116
P/E (12m fwd.)	15.2
EV/EBITDA (2017)	10.6
Dividend yield (2017)	1.9%
EPS growth 2017	4%
EPS growth 12/17	44%
Net debt/Ebitda (2017)	-0.4
ROE (2017)	14%



## Portfolio quoted

Transactions: Introduction Axway



Axway Software offers middleware solutions to support companies in their transition towards higher degrees of digitalisation. Their products are available “on-premise” and as a cloud offering. Axway has been listed in Euronext Paris since June 2011.

### Key figures & ratios 30/06/17

Mkt. Cap. (m EUR)	646
P/E (12m fwd.)	14.4
EV/EBITDA (2017)	10.7
Dividend yield (2017)	1.4%
EPS growth 2017	-3%
EPS growth 12/17	8%
Net debt/Ebitda (2017)	0.2
ROE (2017)	11%



## Portfolio quoted

Transactions: Introduction CEWE



CEWE Stiftung & Co. KGaA ("CEWE") engages in the provision of innovative photo and online printing services, with CEWE PHOTO BOOK as the leading European photo book brand. It operates through the segments Photofinishing, Retail, Commercial Online Printing, and Other Activities. Founded in 1961 by Heinz Neumüller, CEWE was taken to the stock exchange in 1993. The company is headquartered in Oldenburg, Germany.

### Key figures & ratios 30/06/17

Mkt. Cap. (m EUR)	546
P/E (12m fwd.)	14.7
EV/EBITDA (2017)	5.5
Dividend yield (2017)	2.6%
EPS growth 2017	4%
EPS growth 12/17	11%
Net debt/Ebitda (2017)	-0.6
ROE (2017)	16%



## Portfolio quoted Top 10 holdings


	country	sector/activity	portfolio entry	% NAV 30/6/2017
TKH Group	Netherlands	telecom, building and industrial solutions	2014	4.8%
Andritz	Austria	plant engineering	2008	3.8%
Pharmagest	France	software for pharmacies	2010	3.6%
Gerresheimer	Germany	pharma packaging	2011	3.4%
Technotrans	Germany	liquid technology	2015	3.3%
Norma Group	Germany	connection technology and water mgmt.	2016	3.1%
Umicore	Belgium	materials technology	2006	3.0%
Jensen-Group	Germany	heavy-duty laundry equipment	2016	2.8%
Corbion	Netherlands	food ingredients and biobased chemicals	2016	2.7%
Kingspan	Ireland	Insulation materials and products	2016	2.7%



## Portfolio quoted

Valuation of portfolio companies: 12m fwd. P/E = 19.3


12 month forward P/E of portfolio companies at 30/06/2017





# Portfolio quoted Financial strength


## Net debt/EBITDA 2017e of portfolio companies at 30/06/2017





# Portfolio quoted 2017 H1 result

## 2017 H1 portfolio company returns in local currency



Source: Bloomberg, Capricorn Venture Partners  
 QfG quoted (e) is estimate excluding costs and cash  
 (I) = return since introduction, (O) return until removal from portfolio





## Portfolio quoted

### Performance attribution 2017 H1

#### TOP POSITIVE CONTRIBUTIONS

Stock	Contrib. %
1 technotrans AG	2.8
2 TKH Group N.V. Cert	1.9
3 NEXUS AG	1.8
4 Compagnie d'Entreprises CFE SA	1.1
5 USU Software AG	1.0

#### TOP NEGATIVE CONTRIBUTIONS

Stock	Contrib. %
1 Kiadis Pharma NV	-0.4
2 Bertrandt AG	-0.2
3 CEWE Stiftung & Co. KGaA	-0.1
4 Axway Software SA	-0.1
5	

**Estimated gross (excl. fees & cash) performance QfG Quoted Portfolio: 16%**




## Agenda

- 2017 H1 results and performance Quest for Growth
- Comments on quoted portfolio
- Comments on unquoted portfolio
- Questions and Answers



# Portfolio unquoted





## Portfolio unquoted CHF - Trade Sale Ogeda



### **Ogeda's acquisition has positive impact on net asset value Quest for Growth**

Astellas Pharma announced its intention to acquire Ogeda SA (Gosselies, Belgium). Ogeda is a portfolio company of Capricorn Health-tech Fund, in which Quest for Growth participates.

Ogeda (formerly Euroscreen) has been founded in 1994 and is focusing on discovery of small molecules targeting G-Protein Coupled Receptors (GPCRs). It is developing a pipeline of proprietary and partnered products. Its most advanced product is Fezolinetant. Fezolinetant has successfully completed a phase IIa trial in hot flashes.

If the transaction is closed successfully, Quest for Growth expects a positive impact on its NAV of about € 8.6 million or € 0.57 per share. This valuation takes into account a discount on the milestone payments and on the amount that will be kept in escrow.

The announced transaction is the first significant successful divestment of Capricorn Health-tech Fund. Earlier, in 2015, Capricorn ICT Arkiv realised the successful exit of its investment in Cartagena. These transactions confirm that the strategy to invest indirectly in unquoted companies via Capricorn funds can have a strong positive impact on the results of Quest for Growth.

For more information we refer to the website of Ogeda - [www.ogeda.com](http://www.ogeda.com)



## Portfolio unquoted CHF - Trade Sale Ogeda



Astellas Pharma acquired Ogeda SA.

The transaction was closed and the proceeds (Up front payment) were paid to shareholders of Ogeda on May 16th. An escrow on the up front payment is discounted by 20%. Future milestone payments are discounted by respectively 50% and 75%.

On June 29<sup>th</sup>, the general meeting of Capricorn Health-tech Fund approved a capital decrease of € 0,43 per share.

Quest for Growth will receive € 6,450,000 in Q3 2017. The capital decrease is booked as a receivable in the H1 reporting figures.



## Portfolio unquoted CHF - Trade Sale Trinean



Trinean was acquired by Unchained Labs:



[CONTACT](#) [LOGIN](#)

[HOME](#)

[PRODUCTS](#)

[APPLICATIONS](#)

[SERVICE & SUPPORT](#)

[ABOUT US](#)

[WHERE TO BUY](#)

**Trinean** is now part of **UNCHAINED LABS**

DROPSENSE 16



[Take a look at the Unchained Labs' products. Click here](#)



## Portfolio unquoted

### Investments in Venture Funds

	Currency	Last Valuation Date	Valuation in €	in % of Net Asset Value
<b>CAPRICORN VENTURE PARTNERS</b>				
CAPRICORN CLEANTECH FUND	€	30/06/2017	1.114.829	0,71%
CAPRICORN HEALTH-TECH FUND	€	30/06/2017	10.029.069	6,38%
CAPRICORN ICT ARKIV	€	30/06/2017	5.036.919	3,21%
CAPRICORN SUSTAINABLE CHEMISTRY FUND	€	30/06/2017	3.568.500	2,27%
<b>THIRD PARTY FUNDS</b>				
CARLYLE EUROPE TECHNOLOGY PARTNERS I	€	31/03/2017	47.822	0,03%
CARLYLE EUROPE TECHNOLOGY PARTNERS II	€	31/03/2017	1.238.013	0,79%
CETP LP CO-INVESTMENT	£	31/03/2017	73.743	0,05%
LIFE SCIENCES PARTNERS III	€	31/03/2017	518.000	0,33%
LIFE SCIENCES PARTNERS IV	€	31/03/2017	1.861.000	1,18%
SCHRODER VENTURES LSF II	\$	31/12/2016	49.529	0,03%
VENTECH CAPITAL 2	€	31/12/2016	72.006	0,05%
VERTEX III	\$	31/03/2017	992.468	0,63%
			<b>24.601.899</b>	<b>15,66%</b>

Capricorn Venture Partner Funds are valued at the same reporting date (30/06/2017) as the Quest for Growth reporting date. Previously last quarter changes were reflected in a separate line "change in valuation in unquoted companies and venture funds". This will further enhance transparency in reports.



## Portfolio unquoted

Value adjustments not assigned to a specific company or venture capital fund

Total Financial Assets - Shares	€	133.678.960	85,11%
Change in valuation in unquoted companies	€	-2.261.134	-1,44%
Total Financial Assets - Shares after depreciation	€	131.417.826	83,67%

In the unquoted portfolio value adjustments for a total of - € 2,261,134 are booked in a separate line. These value adjustments are booked to reflect uncertainties at certain portfolio companies with respect to future rounds of financing.





## Agenda

- 2016 H1 results and performance Quest for Growth
- Comments on quoted portfolio
- Comments on unquoted portfolio
- Questions and Answers



# Financial calendar 2017

## FINANCIAL CALENDAR

Shareholders' meetings	Annual General Meeting	Thursday March 16th 2017
	Annual General Meeting	Thursday March 29th 2018

Audit committee	Results FY 2016	Tuesday 24 January 2017 at 13h00
	Results Q1	Tuesday 25 April 2017 at 13h00
	Results H1	Tuesday 25 July 2017 at 13h00
	Results Q3	Tuesday 24 October 2017 at 13h00
	Results FY 2017	Tuesday 23 January 2018 at 13h00

Board of directors	Results FY 2016	Tuesday 24 January 2017 at 15h00
	Results Q1	Tuesday 25 April 2017 at 16h00
	Results H1	Tuesday 25 July 2017 at 15h00
	Results Q3	Tuesday 24 October 2017 at 15h00
	Results FY 2017	Tuesday 23 January 2018 at 15h00

Public announcements	Results FY 2016	Thursday 26 January 2017 at 17h40
	Results Q1	Thursday 27 April 2017 at 17h40
	Results H1	Thursday 27 July 2017 at 17h40
	Results Q3	Thursday 26 October 2017 at 17h40
	Results FY 2017	Thursday 25 January 2018 at 17h40

Analyst meetings & Press conferences	Results FY 2016	Friday 27 January 2017 at 11h00
	Results Q1	Friday 28 April 2017 at 11h00
	Results H1	Friday 28 July 2017 at 11h00
	Results Q3	Friday 27 October 2017 at 11h00
	Results FY 2017	Friday 26 January 2018 at 11h00

### Publication of Net Asset Value

2017												
N.A.V.	31 Jan	28 Feb	31 Mar	30 Apr	31 May	30 June	31 July	31 Aug	30 Sep	31 Oct	30 Nov	31 Dec
QfG Website	Thu 2 Feb	Thu 2 Mar	Thu 6 Apr	Thu 4 May	Thu 8 June	Thu 6 July	Thu 3 Aug	Thu 7 Sep	Thu 5 Oct	Thu 2 Nov	Thu 7 Dec	Thu 4 Jan

Publication NAV on QfG website after 17h40



## Agenda

- 2016 H1 results and performance Quest for Growth
- Comments on quoted portfolio
- Comments on unquoted portfolio
- Questions and Answers



*Thank you for your attention!*